کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4263421 | 1284621 | 2006 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (myfortic) in De Novo Renal Transplant Recipients: Results of a 12-Month Multicenter, Open-Label, Prospective Study
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
عمل جراحی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (myfortic) in De Novo Renal Transplant Recipients: Results of a 12-Month Multicenter, Open-Label, Prospective Study Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (myfortic) in De Novo Renal Transplant Recipients: Results of a 12-Month Multicenter, Open-Label, Prospective Study](/preview/png/4263421.png)
چکیده انگلیسی
Enteric-coated mycophenolate sodium (EC-MPS) has been developed as an alternative formulation of mycophenolate acid aiming for improved gastrointestinal (GI) tolerability. This 12-month, open-label, multicenter, prospective study investigated the efficacy and tolerability of EC-MPS (720 mg twice a day) given in combination with cyclosporine microemulsion (CsA-ME) in de novo renal transplant recipients (n = 140). The efficacy evaluation was the incidence of treatment failure (defined as biopsy-proven acute rejection [BPAR], graft loss, or death) after 6 and 12 months of treatment. The incidences of treatment failure, BPAR, and graft loss were comparable at 6 and 12 months (18.6% vs 22.1%, 15.7% vs 19.3%, and 1.4% vs 2.1%, respectively). Renal function at 6 and 12 months (creatinine clearance) was 60.6 ± 19.8 mL/min and 63.2 ± 27.1 mL/min, respectively. EC-MPS was generally well tolerated; 95.9% of the reported GI adverse events (AEs) were rated as mild or moderate. The rate of EC-MPS dose reduction was 26.4%; 4.3% were due to GI AEs. The rate of EC-MPS dose interruption was 10%; 2.1% were due to GI AEs. In summary, EC-MPS given in combination with CsA-ME demonstrates good efficacy and tolerability in de novo renal transplant recipients.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Transplantation Proceedings - Volume 38, Issue 5, June 2006, Pages 1301-1306
Journal: Transplantation Proceedings - Volume 38, Issue 5, June 2006, Pages 1301-1306
نویسندگان
B. Vogt, A. Antoniadis, M. Klinger, S. Vitko,